AI Engines For more Details: Perplexity Kagi Labs You
Fungal Infections: Ciclopirox ethanolamine is primarily indicated for the treatment of fungal infections such as athlete's foot (tinea pedis), jock itch (tinea cruris), ringworm (tinea corporis), and fungal infections of the nails (onychomycosis). It works by disrupting the synthesis of fungal cell membranes, leading to fungal cell death. Ciclopirox ethanolamine is effective against a wide range of dermatophyte fungi, yeast, and mold species responsible for superficial fungal infections.
Tinea Versicolor: Ciclopirox ethanolamine may also be used to treat tinea versicolor, a common fungal infection of the skin caused by the Malassezia yeast. Tinea versicolor typically presents as patches of discolored skin (hypopigmentation or hyperpigmentation) on the chest, back, shoulders, and upper arms. Ciclopirox ethanolamine helps eliminate the yeast overgrowth responsible for tinea versicolor and restores normal pigmentation of the affected skin.
Seborrheic Dermatitis: Ciclopirox ethanolamine may be prescribed for the treatment of seborrheic dermatitis, a chronic inflammatory skin condition characterized by red, scaly patches on the scalp, face, ears, and other areas rich in sebaceous glands. Although the exact cause of seborrheic dermatitis is unknown, it is believed to involve a combination of genetic, environmental, and microbial factors. Ciclopirox ethanolamine helps alleviate symptoms of seborrheic dermatitis by inhibiting the growth of Malassezia yeast and reducing inflammation and scaling of the affected skin.
Topical Solution: Ciclopirox ethanolamine is available as a topical solution or cream for external use. It should be applied to the affected area(s) of the skin or nails according to the healthcare provider's instructions. Treatment duration may vary depending on the type and severity of the fungal infection, ranging from a few weeks to several months. Ciclopirox ethanolamine should be used regularly and as directed to achieve optimal therapeutic outcomes.
Side Effects: Common side effects of ciclopirox ethanolamine may include skin irritation, itching, burning, redness, or stinging at the site of application. These side effects are usually mild and transient and often resolve with continued use. Ciclopirox ethanolamine is generally well-tolerated when used as directed, but individuals with known hypersensitivity to the medication or any of its components should discontinue use and consult their healthcare provider.
Contraindications: Ciclopirox ethanolamine is contraindicated in individuals with a known hypersensitivity to the medication or any of its components. It should not be ingested or applied to mucous membranes such as the eyes, mouth, or vagina. Ciclopirox ethanolamine is for external use only and should not be used on open wounds or broken skin. Pregnant or breastfeeding women should consult their healthcare provider before using ciclopirox ethanolamine.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 0.3 | 0.6 | -1 |
| ADHD | 1.4 | 1.4 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 1.5 | 0.9 | 0.67 |
| Allergies | 1.3 | 0.5 | 1.6 |
| Allergy to milk products | 0.5 | 0.3 | 0.67 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 1 | 4 | -3 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.1 | |
| Ankylosing spondylitis | 1 | 0.9 | 0.11 |
| Anorexia Nervosa | 0.6 | 1.8 | -2 |
| Antiphospholipid syndrome (APS) | 1.1 | 0.3 | 2.67 |
| Asthma | 1.8 | 1.4 | 0.29 |
| Atherosclerosis | 0.4 | 1.3 | -2.25 |
| Atrial fibrillation | 1.4 | 1 | 0.4 |
| Autism | 3.6 | 2.5 | 0.44 |
| Autoimmune Disease | 0.3 | 0.7 | -1.33 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.8 | 1.8 | |
| Bipolar Disorder | 0.8 | 0.8 | 0 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Cancer (General) | 0.3 | 0.7 | -1.33 |
| Carcinoma | 1 | 0.4 | 1.5 |
| Celiac Disease | 1.6 | 1 | 0.6 |
| Cerebral Palsy | 1.1 | 1 | 0.1 |
| Chronic Fatigue Syndrome | 1.8 | 1.3 | 0.38 |
| Chronic Kidney Disease | 1.8 | 1.9 | -0.06 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 1.1 | 0.09 |
| Chronic Urticaria (Hives) | 0.8 | 0.1 | 7 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 1 | -2.33 |
| Cognitive Function | 1.2 | 1 | 0.2 |
| Colorectal Cancer | 3.3 | 1.3 | 1.54 |
| Constipation | 0.3 | 0.7 | -1.33 |
| Coronary artery disease | 1.2 | 1.8 | -0.5 |
| COVID-19 | 1.4 | 3.4 | -1.43 |
| Crohn's Disease | 2.7 | 1.5 | 0.8 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1 | -1 | |
| deep vein thrombosis | 0.8 | 1.1 | -0.38 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 2.6 | 3.5 | -0.35 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.4 | 0.6 | 1.33 |
| Endometriosis | 0.7 | 0.8 | -0.14 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 1.3 | 0.4 | 2.25 |
| erectile dysfunction | 1.1 | 1.1 | |
| Fibromyalgia | 0.9 | 0.5 | 0.8 |
| Functional constipation / chronic idiopathic constipation | 1.5 | 1.9 | -0.27 |
| gallstone disease (gsd) | 1.3 | 0.5 | 1.6 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.3 | 0.33 |
| Generalized anxiety disorder | 1.3 | 1.3 | 0 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.2 | 2 |
| Graves' disease | 0.6 | 1.5 | -1.5 |
| Gulf War Syndrome | 0.6 | 0.3 | 1 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 1.9 | 1.2 | 0.58 |
| Heart Failure | 1.4 | 1.1 | 0.27 |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1.3 | 1.3 | |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 0 | 0.4 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 1.3 | 2.1 | -0.62 |
| Hypothyroidism | 0.1 | -0.1 | |
| Hypoxia | 1 | 1 | |
| IgA nephropathy (IgAN) | 0.6 | 1.8 | -2 |
| Inflammatory Bowel Disease | 2.7 | 3.2 | -0.19 |
| Insomnia | 1 | 1.8 | -0.8 |
| Intelligence | 0.5 | 0.5 | |
| Intracranial aneurysms | 0.4 | 0.4 | |
| Irritable Bowel Syndrome | 3.2 | 1.6 | 1 |
| ischemic stroke | 1 | 1.1 | -0.1 |
| Liver Cirrhosis | 2.7 | 1.9 | 0.42 |
| Long COVID | 2.1 | 1.8 | 0.17 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.3 | 0.1 | 2 |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.5 | 0.3 | 0.67 |
| ME/CFS without IBS | 1.1 | 0.3 | 2.67 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 2.4 | 2.4 | 0 |
| Mood Disorders | 3.1 | 2.6 | 0.19 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 2 | 2.5 | -0.25 |
| Multiple system atrophy (MSA) | 0.9 | 0.1 | 8 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 1.1 | -1.1 | |
| Neuropathy (all types) | 0.4 | 0.5 | -0.25 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.5 | 1.4 | 0.07 |
| NonCeliac Gluten Sensitivity | 0.4 | 0.3 | 0.33 |
| Obesity | 3.2 | 2.3 | 0.39 |
| obsessive-compulsive disorder | 1 | 2.2 | -1.2 |
| Osteoarthritis | 1.5 | 0.6 | 1.5 |
| Osteoporosis | 1.3 | 0.7 | 0.86 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 2.3 | 3.1 | -0.35 |
| Polycystic ovary syndrome | 2.2 | 1.7 | 0.29 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | |
| Premenstrual dysphoric disorder | 0.1 | 0.1 | |
| primary biliary cholangitis | 0.6 | 0.5 | 0.2 |
| Primary sclerosing cholangitis | 1.7 | 1 | 0.7 |
| Psoriasis | 1 | 1.3 | -0.3 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.1 | 2 | 0.05 |
| Rosacea | 0.6 | 0.7 | -0.17 |
| Schizophrenia | 2 | 1.5 | 0.33 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.7 | 0.7 | 0 |
| Sleep Apnea | 0.1 | 1 | -9 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 1.1 | |
| Stress / posttraumatic stress disorder | 1 | 0.8 | 0.25 |
| Systemic Lupus Erythematosus | 2.2 | 0.7 | 2.14 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.6 | 1.3 | 0.23 |
| Type 2 Diabetes | 2.5 | 2 | 0.25 |
| Ulcerative colitis | 1.8 | 1.9 | -0.06 |
| Unhealthy Ageing | 2.4 | 1 | 1.4 |
| Vitiligo | 0.7 | 0.2 | 2.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
